EUVIMEDEUVIMED entdecken
Crossref

2‐Oxoquinoline‐based‐thiosemicarbazones as multitargeting neurotherapeutics against Alzheimer's disease: In vitro and in silico studies of MAO and ChE inhibitors

Rabia Basri, Shamool Fatima, Saquib Jalil, Aqeel Imran, Noor Fatima, Asad Syed, Ali H Bahkali, Jamshed Iqbal, Zahid Shafiq

Archiv der Pharmazie · 2023

DOI: 10.1002/ardp.202300430 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archiv der Pharmazie, 2023. Verfasst von Rabia Basri und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Chemical Sciences, Bahauddin Zakariya University, Multan, Pakistan. Hauptthemen laut MEDLINE: Alzheimer Disease, Thiosemicarbazones, Quinolones. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: King Saud University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Alzheimer's disease (AD) presents a multifactorial neurological disorder with multiple enzyme involvement in its onset. Conventional monotherapies fall short in providing long‐term relief, necessitating the exploration of alternative multitargeting approaches to address the complexity of AD. Therefore, the design, synthesis, and in vitro and in silico evaluation of 2‐oxoquinoline‐based thiosemicarbazones 9a–r as multipotent analogs, able to simultaneously inhibit the cholinesterase (ChE) and monoamine oxidase (MAO) enzymes for the potential treatment of AD, are reported. In the in vitro experimental evaluation of MAO and ChE inhibition, all tested compounds demonstrated remarkable potency exhibiting nonselective inhibition of both MAO‐A and MAO‐B, and selective inhibition of acetylcholinesterase (AChE) over butyrylcholinesterase (BChE), with 9d , 9j , and 9m evolving as lead compounds for MAO‐A, MAO‐B, and AChE, displaying IC 50 values of 0.35 ± 0.92, 0.50 ± 0.02, and 0.25 ± 0.13 μM, respectively. Moreover, the kinetic studies revealed that all tested compounds inhibited all three enzymes through a competitive mode of inhibition. Furthermore, the molecular docking studies of the most active compounds revealed several crucial interactions, particularly hydrogen bonding interactions. These interactions were observed between the nitrogen and sulfur atoms of thiosemicarbazone and the nitrogen and oxygen atoms of the quinoline ring with various amino acids, suggesting the strong interactions of these compounds with the enzymes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseThiosemicarbazonesQuinolonesHumansCholinesterase InhibitorsMonoamine OxidaseButyrylcholinesteraseAcetylcholinesteraseMonoamine Oxidase InhibitorsMolecular Docking SimulationKineticsStructure-Activity RelationshipNitrogen

Stichwörter der Autor:innen

anti-Alzheimercholinesterasemolecular dockingmonoamine oxidasethiosemicarbazone

Substanzen

Cholinesterase InhibitorsMonoamine OxidaseButyrylcholinesteraseAcetylcholinesteraseMonoamine Oxidase InhibitorsThiosemicarbazonesQuinolonesNitrogen

Autor:innen und Institutionen

  • Institute of Chemical Sciences, Bahauddin Zakariya University, Multan, Pakistan.
  • Department of Chemistry, Quaid-i-Azam University, Islamabad, Pakistan.
  • Centre for Advanced Drug Research, COMSATS University Islamabad, Abbottabad Campus, Abbottabad, Pakistan.
  • Department of Pharmacy, COMSATS University Islamabad, Lahore Campus, Islamabad, Punjab, Pakistan.
  • Department of Botany and Microbiology, King Saud University, Riyadh, Saudi Arabia.
  • Department of Chemistry, COMSATS University Islamabad, Abbottabad Campus, Abbottabad, Pakistan.

Förderung

  • King Saud University

Zitieren

APA

Basri, R., Fatima, S., Jalil, S., Imran, A., Fatima, N., Syed, A., Bahkali, A. H., Iqbal, J., & Shafiq, Z. (2023). 2‐Oxoquinoline‐based‐thiosemicarbazones as multitargeting neurotherapeutics against Alzheimer's disease: In vitro and in silico studies of MAO and ChE inhibitors. Archiv der Pharmazie. https://doi.org/10.1002/ardp.202300430

Vancouver

Basri R, Fatima S, Jalil S, Imran A, Fatima N, Syed A, et al. 2‐Oxoquinoline‐based‐thiosemicarbazones as multitargeting neurotherapeutics against Alzheimer's disease: In vitro and in silico studies of MAO and ChE inhibitors. Archiv der Pharmazie. 2023. doi:10.1002/ardp.202300430

BibTeX
@article{Basri2023,
  author = {Basri, Rabia and Fatima, Shamool and Jalil, Saquib and Imran, Aqeel and Fatima, Noor and Syed, Asad and Bahkali, Ali H and Iqbal, Jamshed and Shafiq, Zahid},
  title = {2‐Oxoquinoline‐based‐thiosemicarbazones as multitargeting neurotherapeutics against Alzheimer's disease: In vitro and in silico studies of MAO and ChE inhibitors},
  journal = {Archiv der Pharmazie},
  year = {2023},
  doi = {10.1002/ardp.202300430}
}
Kostenlos starten →